Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.70 |
| ▸ | POLA1 | P09884 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320235 | 0.87 | KCNH2 (0.66) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6481567 | 0.84 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL6363622 | 0.82 | KCNH2 (1.00) | KCNH2POLA1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7542126 | 0.82 | KCNH2 (0.98) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL7057291 | 0.81 | KCNH2 (0.52) | KCNH2MEN1KMT2A | |
| SCHEMBL6685960 | 0.81 | KCNH2 (0.52) | KCNH2MEN1KMT2A | |
| SCHEMBL6685956 | 0.81 | KCNH2 (0.52) | KCNH2MEN1KMT2A | |
| SCHEMBL6288599 | 0.81 | KCNH2 (0.70) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6478861 | 0.79 | KCNH2 (0.75) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6479791 | 0.77 | ALDH1A1 (0.47) | KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-6831081-B2 | Herpes virus including simplex types 1 and 2, varicella zoster, human cytomegalovirus, Epstein-Barr and human 6, 7 and 8 | PHARMACIA & UPJOHN | 2004-12-14 | — | — | US | disclosed |
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, MAVS | KCNH2 1376/4885POLA1 982/4885MEN1 4473/4885 |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | KCNH2 819/4885POLA1 1614/4885MEN1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.